Insmed Incorporated
INSM
Peringkat dalam Saham
#1117
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Harga Saham
$95.40
Kapitalisasi Pasar
$20.83B
Perubahan (1 hari)
0.12%
Perubahan (1 tahun)
-43.18%
Negara
US
Perdagangan Insmed Incorporated (INSM)
Kategori
Healthcare
Rasio P/S untuk Insmed Incorporated (INSM)
Rasio P/S per October 2026 TTM: 18.77
Menurut laporan keuangan dan harga saham terbaru dari Insmed Incorporated, rasio P/S saat ini (TTM) adalah 18.77. Pada akhir 2023, rasio P/S perusahaan adalah 14.26.
Riwayat rasio P/S untuk Insmed Incorporated dari 2000 hingga 2026
Rasio P/S pada akhir setiap tahun
| Tahun | Rasio P/S | Mengubah |
|---|---|---|
| 2026 (TTM) | 18.77 | -39.72% |
| 2024 | 31.14 | 118.38% |
| 2023 | 14.26 | 42.32% |
| 2022 | 10.02 | -38.17% |
| 2021 | 16.20 | -18.01% |
| 2020 | 19.76 | 33.56% |
| 2019 | 14.80 | -85.57% |
| 2018 | 102.51 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | 57.87 | 11.92% |
| 2013 | 51.71 | 0.00% |
| 2012 | 0.00 | -100.00% |
| 2011 | 16.12 | 33.50% |
| 2010 | 12.08 | 27.98% |
| 2009 | 9.44 | 93.34% |
| 2008 | 4.88 | -61.16% |
| 2007 | 12.57 | -85.15% |
| 2006 | 84.64 | -88.45% |
| 2005 | 732.99 | 16.61% |
| 2004 | 628.56 | -10.83% |
| 2003 | 704.88 | 9,371.65% |
| 2002 | 7.44 | -98.25% |
| 2001 | 424.21 | -59.94% |
| 2000 | 1.06K | 0.00% |
Rasio P/S untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/S | Perbedaan Rasio P/S | Negara |
|---|---|---|---|
| 10.02 | -46.61% |
US
|
|
| 40.55 | 116.02% |
US
|
|
| 3.96 | -78.90% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -45.95% |
NL
|
